Literature DB >> 3044632

An autoradiographic study of the intrarenal localisation and retention of cisplatin, iproplatin and paraplatin.

C Ewen1, A Perera, J H Hendry, C A McAuliffe, H Sharma, B W Fox.   

Abstract

The intrarenal localisation of platinum following the intravenous administration of platinum-195m-labelled cisplatin, iproplatin and paraplatin was studied using autoradiography. Following injection of cisplatin, platinum was distributed throughout the kidney even up to 14 days after treatment. In the case of iproplatin and paraplatin rapid platinum clearance was noted from the glomeruli, blood vessels and renal medulla within 2 h of administration. Relative cortical and medullary platinum radionuclide concentrations for all three agents were determined by Chalkley grid analysis. This showed greater relative concentrations of platinum in the cortex at increasing times following iproplatin and paraplatin compared with cisplatin. It is suggested that the lower renal toxicity of iproplatin and paraplatin than of cisplatin may be due to reduced platinum retention within the pars recta.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3044632     DOI: 10.1007/BF00273418

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  15 in total

1.  The nephrotoxic effects of cis-diammine-dichloroplatinum (II) (NSC-119875) in male F344 rats.

Authors:  J M Ward; K A Fauvie
Journal:  Toxicol Appl Pharmacol       Date:  1976-12       Impact factor: 4.219

2.  Some observations on the normal and pathologic anatomy of the kidney of the mouse.

Authors:  T B DUNN
Journal:  J Natl Cancer Inst       Date:  1949-02       Impact factor: 13.506

Review 3.  New platinum complexes in clinical trials.

Authors:  F H Lee; R Canetta; B F Issell; L Lenaz
Journal:  Cancer Treat Rev       Date:  1983-03       Impact factor: 12.111

4.  Evaluation of the nephrotoxicity of iproplatin (CHIP) in comparison to cisplatin by the measurement of urinary enzymes.

Authors:  L Pendyala; S Madajewicz; S B Lele; S G Arbuck; P J Creaven
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

5.  Long-term consequences of cis-platinum-induced renal injury: a structural and functional study.

Authors:  D C Dobyan
Journal:  Anat Rec       Date:  1985-07

6.  Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity.

Authors:  M P Goren; A A Forastiere; R K Wright; M E Horowitz; R K Dodge; B A Kamen; M J Viar; C B Pratt
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

7.  A comparative study of the distribution in the male rat of platinum-labelled cis-dichlorodiammine platinum (II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum (I), and cis-dichloro-bis-cyclopropylamine platinum (II).

Authors:  R Harrison; C A McAuliffe; A Zaki; J Baer; H Sharma; A Smith; H Jackson; B W Fox
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

8.  Ischemic damage and repair in the rat proximal tubule: differences among the S1, S2, and S3 segments.

Authors:  M A Venkatachalam; D B Bernard; J F Donohoe; N G Levinsky
Journal:  Kidney Int       Date:  1978-07       Impact factor: 10.612

9.  Cis-diamminedichloroplatinum (II)-induced acute renal failure in the rat. Correlation of structural and functional alterations.

Authors:  T W Jones; S Chopra; J S Kaufman; W Flamenbaum; B F Trump
Journal:  Lab Invest       Date:  1985-04       Impact factor: 5.662

10.  Phase I studies with carboplatin at the Royal Marsden Hospital.

Authors:  A H Calvert; S J Harland; D R Newell; Z H Siddik; K R Harrap
Journal:  Cancer Treat Rev       Date:  1985-09       Impact factor: 12.111

View more
  3 in total

1.  Preclinical imaging characteristics and quantification of Platinum-195m SPECT.

Authors:  E A Aalbersberg; B J de Wit-van der Veen; O Zwaagstra; K Codée-van der Schilden; E Vegt; Wouter V Vogel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-11       Impact factor: 9.236

Review 2.  Platinum antitumour agents: a review of (bio)analysis.

Authors:  T J Hodes; W J Underberg; G Los; J H Beijnen
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

Review 3.  Clinical pharmacokinetics of carboplatin.

Authors:  W J van der Vijgh
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.